Member Info for E_AL

TroytoTiber, Gynia Holdings is the company’s major shareholder and it holds 82.66% of the shares so there isn’t many shares out there for public to trade which can results in significant drops similar to what we witnessed over the past couple of days or rapid rebounds

I just added, the most recent trading update looks decent , the main shareholder Gynia Holdings holds 82.66% of the shares, which means limited shares are available for public . Consequently, small trading volumes could cause significant drops or rapid rebounds in the share price. Currently, it's heavily oversold across daily, weekly, and monthly tech charts, so I see the share price at least double in the short term.

Looks like it bounced off the 8DMA :)

The share price is testing the 8 Days moving average trend atm which is the current support on the technical chart.

The asset is significantly oversold based on the daily and weekly technical charts and it's NT to buy at the moment. To me, it seems like this drop was a deliberate move to trigger any remaining stop losses before the results are announced. I will buy here and hold for the results

From the latest trading update:

Business Metrics:

· Cash: $13.9m as of 31 December 2023

· Total 2023 revenue and other income: $17.5m, a 2.8x increase over FY22

o Accrufer® revenue: $11.6m, a 3.1x increase over FY22

o Ex-U.S. revenue: $1.5m

o Other income revenue including Viatris milestone payments: $4.4m

· U.S. Q4 2023 Revenue: $4.3m

· Average net selling price: c.$145/prescription in H2 2023, an increase of c.21% compared with H1 2023

· Total 2023 Prescriptions: c.77k, a 3.1x increase over FY22

It seems someone is accumulating shares at these low prices , near all-time lows causing the share price to repeatedly cross the 140 line . Whenever the share price starts to rise to the 140s, they target the BID to bring it back down and repeat the cycle. It's likely to rebound soon ; you can only squeeze so much from a dry lemon.

Recording of ITM POWER PLC Interim Results presentation, along with responses to questions that were answered by the company has just been published:

Link to the presentation:

https://www.investormeetcompany.com/investor/meeting/interim-results-273/presentation

Link to the Q&A :

https://www.investormeetcompany.com/meetings/interim-results-273

PRESENTERS:

Answered by:

Dennis Schulz - CEO

Andy Allen - CFO

Justin Scarborough - Head of Investor Relations

I watched the latest video call and they said the available cash is sufficient to cover them until probability early next year .

From the latest trading update :

Cash: $13.9m as of 31 December 2023

For the year ended December 31, Shield said it had delivered USD17.5 million in revenue, up nearly three-fold from USD6.2 million in 2022.

28 Sep 2023 RNS:

The Company is also pleased to announce that it has secured a US$20m senior secured debt facility from SWK (the "SWK Financing"), a life science-focused specialty finance company catering for small and mid-sized commercial-stage companies.

Was this your 'small position' mate? ;)

09-Apr-24 09:48:01 1.72 1,150,000 Buy* 1.65 1.75 £19.78k

Same here mate & I expect many have done the same last week to realise the loss before the end of the tax year ;)

It appears that a fund is attempting to trigger as many PIs stop losses as possible before the results are released to load up on the cheap until the share price starts to show some resistance/bounce back

The sp is climbing back up :)

Did I read it correct?

- Retail Offer shall not exceed £200,000. ( available for individual shareholders- aka the minions)

-A placing and subscription to raise approximately £2.0 million - from whom?? The company’s Major shareholders? So I take it this placing isn’t available for individual shareholders ?

The rapid decline in share price coupled with AOP Health's significant stake as the company closed the year with total sales of $17.5 million, a significant increase from $6.2 million a year prior, largely driven by robust demand for its iron deficiency treatment, Accrufer, suggests to me a potential imminent takeover. If you examine this article, you'll notice parallels between the current scenario and the situations preceding AOP's takeovers of Amomed and SciPharm.

In May 2023, AOP Health made a cash takeover bid of £46.1 million (equivalent to 6.2 pence per share) for Shield Therapeutics plc (Shield), which represents twice the current share price. I am confident that if AOP Health were to make the same offer tomorrow, they would likely secure the necessary votes from the majority of other shareholders.

*AOP Orphan takes over two healthcare companies:

https://www.aop-health.com/global_en/press/press-releases/rare-disease-pioneer-aop-orphan-takes-over-two-health-care-companies-strengthening-its-position-in-europe-as-well-as-vienna-as-a-research-and-business-hub/

Not another Amigo FFS .................

Frankie1x, we have several major shareholders, each holding less than 5% of the company's shares. This percentage serves as the requisite threshold for UK companies to inform the market of any changes in their holdings through a TR1 notification.

Jupiter Asset Management Ltd 4.364 %

Premier Fund Managers Ltd. 3.836 %

LGT Capital Partners AG (Investment Management) 3.669 %

KW Investment Management Ltd. 2.641 %

Jarvis Investment Management Ltd. 1.680 %

Given the substantial number of shares traded at the end of last month, I am inclined to believe that at least two major shareholders have offloaded their shares to the market and cashed out.

Regardless, the past is behind us, and we've observed a nice buying momentum gaining traction since the start of this week. I can see the share price smoothly rise back to the 4s from its current level. The technical chart is currently indicating a significant oversold condition on both the weekly and daily charts, making it an appealing prospect for chart and momentum traders as well.

Tax-loss harvesting strategy:

Selling shares at a loss before the end of the tax year allows holders to offset capital gains and reduce their overall taxable income. This strategy, known as tax-loss harvesting, helps minimize taxes by utilizing investment losses to counterbalance gains elsewhere in their portfolio.

Nothing is available on the ASK & I can sell all of my position at the ASK price. It looks like it’s time for the SP to climb back up

Top up time for me! I was wating for the sp to re-test ATL around 2.5-2.6 . The sp is heavily oversold on the technical chart & I am expecting some recovery from this level

It looks like there is a seller in the background, most of the sell volumes have been in round numbers